RO105958B1 - Procedeu pentru prepararea unor derivati de aminofenol - Google Patents
Procedeu pentru prepararea unor derivati de aminofenol Download PDFInfo
- Publication number
- RO105958B1 RO105958B1 RO145922A RO14592290A RO105958B1 RO 105958 B1 RO105958 B1 RO 105958B1 RO 145922 A RO145922 A RO 145922A RO 14592290 A RO14592290 A RO 14592290A RO 105958 B1 RO105958 B1 RO 105958B1
- Authority
- RO
- Romania
- Prior art keywords
- alkyl
- phenyl
- pyrazol
- dimethyl
- different
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 title description 2
- -1 CONR12R13 Chemical group 0.000 claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 29
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 11
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 11
- 125000001424 substituent group Chemical group 0.000 claims abstract description 11
- 150000002367 halogens Chemical class 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000001408 amides Chemical class 0.000 claims abstract description 8
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 5
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 5
- 125000004385 trihaloalkyl group Chemical group 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims abstract 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 57
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000013375 chromatographic separation Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical compound C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229940049953 phenylacetate Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- UQFHJDVUQSAVOQ-UHFFFAOYSA-N (2-aminophenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1N UQFHJDVUQSAVOQ-UHFFFAOYSA-N 0.000 description 2
- BVSPFUXVEQLQQQ-UHFFFAOYSA-N (4-amino-2,6-dimethylphenyl) acetate Chemical compound CC(=O)OC1=C(C)C=C(N)C=C1C BVSPFUXVEQLQQQ-UHFFFAOYSA-N 0.000 description 2
- NXXYKOUNUYWIHA-UHFFFAOYSA-N 2,6-Dimethylphenol Chemical compound CC1=CC=CC(C)=C1O NXXYKOUNUYWIHA-UHFFFAOYSA-N 0.000 description 2
- RMFCEMIAAFPZDW-UHFFFAOYSA-N 2,6-dimethyl-4-[(1-phenylpyrazol-3-yl)amino]phenol Chemical compound CC1=C(O)C(C)=CC(NC2=NN(C=C2)C=2C=CC=CC=2)=C1 RMFCEMIAAFPZDW-UHFFFAOYSA-N 0.000 description 2
- WTRUWCXTRLJNLY-UHFFFAOYSA-N 2,6-ditert-butyl-4-[methyl-(1-phenylpyrazol-3-yl)amino]phenol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1N(C)C(=N1)C=CN1C1=CC=CC=C1 WTRUWCXTRLJNLY-UHFFFAOYSA-N 0.000 description 2
- QENUTIJJGGTTPE-UHFFFAOYSA-N 2-phenyl-3,4-dihydropyrazol-5-amine Chemical compound C1CC(N)=NN1C1=CC=CC=C1 QENUTIJJGGTTPE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- OMVFXCQLSCPJNR-UHFFFAOYSA-N 4-amino-2,6-dimethylphenol Chemical compound CC1=CC(N)=CC(C)=C1O OMVFXCQLSCPJNR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000003245 coal Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- DZNLTOBDYCIYSF-UHFFFAOYSA-N (2-aminophenyl) 2-cyanoacetate Chemical compound C(#N)CC(=O)OC1=C(C=CC=C1)N DZNLTOBDYCIYSF-UHFFFAOYSA-N 0.000 description 1
- ZBYADULSWMAJBE-UHFFFAOYSA-N (2-aminophenyl) 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1C(=O)OC1=CC=CC=C1N ZBYADULSWMAJBE-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- TZASZCQVZPLXHP-UHFFFAOYSA-N 2,6-dimethyl-3-nitrophenol Chemical compound CC1=CC=C([N+]([O-])=O)C(C)=C1O TZASZCQVZPLXHP-UHFFFAOYSA-N 0.000 description 1
- LGUUVWVZPNJXFQ-UHFFFAOYSA-N 2,6-dimethyl-4-[methyl-(1-phenylpyrazol-3-yl)amino]phenol Chemical compound C=1C(C)=C(O)C(C)=CC=1N(C)C(=N1)C=CN1C1=CC=CC=C1 LGUUVWVZPNJXFQ-UHFFFAOYSA-N 0.000 description 1
- ZQZAHPFFZWEUCL-UHFFFAOYSA-N 2-chloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1Cl ZQZAHPFFZWEUCL-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- WJQOZHYUIDYNHM-UHFFFAOYSA-N 2-tert-Butylphenol Chemical compound CC(C)(C)C1=CC=CC=C1O WJQOZHYUIDYNHM-UHFFFAOYSA-N 0.000 description 1
- AYGSNWBJTYYNQI-UHFFFAOYSA-N 3,6-dimethoxy-2-methylphenol Chemical compound COC1=CC=C(OC)C(O)=C1C AYGSNWBJTYYNQI-UHFFFAOYSA-N 0.000 description 1
- ZQHUYIQAARXNGI-UHFFFAOYSA-N 3-amino-2,5-dimethoxy-6-methyl-4-(1-phenylpyrazol-3-yl)phenol Chemical compound COC=1C(=C(C(=C(C=1C1=NN(C=C1)C1=CC=CC=C1)N)OC)O)C ZQHUYIQAARXNGI-UHFFFAOYSA-N 0.000 description 1
- KHNNKIICTZLGMR-UHFFFAOYSA-N 3-amino-2,6-dichloro-4-(1-phenylpyrazol-3-yl)phenol Chemical compound ClC1=C(C(=CC(=C1N)C1=NN(C=C1)C1=CC=CC=C1)Cl)O KHNNKIICTZLGMR-UHFFFAOYSA-N 0.000 description 1
- IBKZXBCAHIUVQH-UHFFFAOYSA-N 3-amino-2,6-dimethyl-4-(1-phenylpyrazol-3-yl)phenol Chemical compound CC1=C(C(=CC(=C1N)C1=NN(C=C1)C1=CC=CC=C1)C)O IBKZXBCAHIUVQH-UHFFFAOYSA-N 0.000 description 1
- OTCMKDPJWMNLRD-UHFFFAOYSA-N 3-amino-2,6-dimethyl-4-pyrazin-2-ylphenol Chemical compound CC1=C(C(=CC(=C1N)C1=NC=CN=C1)C)O OTCMKDPJWMNLRD-UHFFFAOYSA-N 0.000 description 1
- DUNUHMLDWFQRIU-UHFFFAOYSA-N 3-amino-4-(4-chloro-6-methylpyrimidin-2-yl)-2,6-dimethylphenol Chemical compound ClC1=NC(=NC(=C1)C)C1=C(C(=C(C(=C1)C)O)C)N DUNUHMLDWFQRIU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YPKCOJPZSAGCHD-UHFFFAOYSA-N 4-(benzimidazol-1-yl)phenol Chemical compound C1=CC(O)=CC=C1N1C2=CC=CC=C2N=C1 YPKCOJPZSAGCHD-UHFFFAOYSA-N 0.000 description 1
- NMCOMWIWQXYSDS-UHFFFAOYSA-N 4-amino-2,3,4,5-tetramethylcyclohexa-1,5-dien-1-ol Chemical compound CC1C(C)=C(O)C=C(C)C1(C)N NMCOMWIWQXYSDS-UHFFFAOYSA-N 0.000 description 1
- NLRKABLJZQSDRO-UHFFFAOYSA-N 4-amino-2,6-ditert-butyl-3-(1-phenylpyrazol-3-yl)phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(N)=C1C1=NN(C=2C=CC=CC=2)C=C1 NLRKABLJZQSDRO-UHFFFAOYSA-N 0.000 description 1
- ADMDZPQWKDHLFB-UHFFFAOYSA-N 4-amino-3,6-dimethoxy-2-methylphenol Chemical compound COC1=CC(N)=C(OC)C(C)=C1O ADMDZPQWKDHLFB-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- LQWOEMYCYLELTP-UHFFFAOYSA-N 5-(2-aminophenyl)-2,6-dimethyl-4-(1-phenylpyrazol-3-yl)pyridine-3-carboxylic acid Chemical compound CC1=C(C(=C(C(=N1)C)C(=O)O)C2=NN(C=C2)C3=CC=CC=C3)C4=CC=CC=C4N LQWOEMYCYLELTP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical class NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 101000620014 Arabidopsis thaliana Linoleate 9S-lipoxygenase 5 Proteins 0.000 description 1
- GQTNZUDDGAPJMW-UHFFFAOYSA-N CC1=CC(C2=NN(C=C2)C=2C=CC=CC=2)=CC=C1C(N)OC(C)(C(O)=O)C1=CC=CC=C1 Chemical compound CC1=CC(C2=NN(C=C2)C=2C=CC=CC=2)=CC=C1C(N)OC(C)(C(O)=O)C1=CC=CC=C1 GQTNZUDDGAPJMW-UHFFFAOYSA-N 0.000 description 1
- AJVWANDLSWZMDP-UHFFFAOYSA-N CC1=CC=CC=C1C(C)(C(C(C2=NN(C=C2)C3=CC=CC=C3)C(=O)O)N)C(=O)OC Chemical compound CC1=CC=CC=C1C(C)(C(C(C2=NN(C=C2)C3=CC=CC=C3)C(=O)O)N)C(=O)OC AJVWANDLSWZMDP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GHORPKYJSATAAS-UHFFFAOYSA-N NC=1C(=C(C(=CC1)CC=C)O)CC=C Chemical compound NC=1C(=C(C(=CC1)CC=C)O)CC=C GHORPKYJSATAAS-UHFFFAOYSA-N 0.000 description 1
- BQICTTOMFGWLGP-UHFFFAOYSA-N O-[2,3,5,6-tetramethyl-4-(1-phenylpyrazol-3-yl)phenyl]hydroxylamine Chemical compound CC1=C(C(=C(C(=C1C)C1=NN(C=C1)C1=CC=CC=C1)C)C)ON BQICTTOMFGWLGP-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- PKYTUEZGROXTPQ-UHFFFAOYSA-N [2,6-dimethyl-4-[(1-phenylpyrazol-3-yl)amino]phenyl] 2-chloroacetate Chemical compound CC1=C(OC(=O)CCl)C(C)=CC(NC2=NN(C=C2)C=2C=CC=CC=2)=C1 PKYTUEZGROXTPQ-UHFFFAOYSA-N 0.000 description 1
- IHPAEFCSKGIMRS-UHFFFAOYSA-N [2,6-dimethyl-4-[(1-phenylpyrazol-3-yl)amino]phenyl] 2-oxopropanoate Chemical compound C1=C(C)C(OC(=O)C(=O)C)=C(C)C=C1NC1=NN(C=2C=CC=CC=2)C=C1 IHPAEFCSKGIMRS-UHFFFAOYSA-N 0.000 description 1
- XCQWBTDXTTYPDL-UHFFFAOYSA-N [2,6-dimethyl-4-[(1-phenylpyrazol-3-yl)amino]phenyl] acetate Chemical compound C1=C(C)C(OC(=O)C)=C(C)C=C1NC1=NN(C=2C=CC=CC=2)C=C1 XCQWBTDXTTYPDL-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002641 lithium Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RRGKOFFIQZTPRH-UHFFFAOYSA-N phenyl 2-methoxyacetate Chemical compound COCC(=O)OC1=CC=CC=C1 RRGKOFFIQZTPRH-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- XRVQTYPOPTUZRF-UHFFFAOYSA-N phenyl hydrogen sulfite Chemical class OS(=O)OC1=CC=CC=C1 XRVQTYPOPTUZRF-UHFFFAOYSA-N 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Cosmetics (AREA)
Description
Prezenta invenție se referă la un procedeu pentru prepararea unor derivați de aminofenol, cu proprietăți antii,nflamatoare, care prezintă formula generală I:
în care R, reprezintă C(O)YZ, Y reprezintă o legătură simplă, O, NRn sau CO, Z reprezintă un atom de hidrogen, un radical alchil sau alchil substituit cu unul sau mai mulți substituenți, aleși dintre hidroxi, alcoxi, aciloxi, carboxi, alfcoxicarbonil, CONRUR13, arilalcoxi, Ar(, heterociclu, halogen, cian sau NR14Rl5, R2, Rj, Rj și R5, care pot fi identici sau diferiți, reprezintă atomi de hidrogen, radicali alchil, alcoxi sau halogen; R4 și Rn, care pot fi identici sau diferiți, reprezintă atomi de hidrogen sau radicali alchil, X reprezintă pirazolil substituit cu Ar2; Ar, și Ar2, care pot fi identici sau diferiți, reprezintă radicali arii sau arii substituit cu unul sau mai mulți substituenți, aleși dintre halogen, nitro, alcoxi, cărboxi, alchil sau trihaloalchil; Rn, R^, R,4, R,j, R 16» ^17» R„, ȘÎ R19, care pot fi identici sau diferiți, reprezintă atomi de hidrogen, radicali alchil sau benziloxicarbonil sau un derivat acceptabil farmaceutic al acestuia, și anume, un N-oxid, N-alchil, o sare, un ester sau o amidă, pentru utilizare ca produs farmaceutic.
Sunt cunoscute procedee pentru prepararea unor compuși cu proprietăți antiinflamatoare pe bază de acid [(dihidroxifenil) alcoxi] benzoic sau 1-(4-hidroxifenil) benzimidazol (EP 310126).
Procedeul, conform invenției, lărgește gama compușilor cu proprietăți antiinflamatoare, prin aceea că se esterifică un compus cu formula generală II:
in care, X, R2, R3, R4, Rs, și R0 au semnificațiile de mai sus, cu un compus cu formula generală III:
R,L, (III) în care R, are semnificația de mai sus și L2 este o grupă scindabilă, cum este o clorură sau O-acil, în prezența unei baze, cum este trietilamina sau dimetilaminopiridina, intr-un solvent inert, cum este diclormetanul sau tetrahidrofuranul, iar dacă se dorește sau este necesar, se îndepărtează grupa protectoare dintr-un compus cu formula generală I, care are o grupă OH, NHR14 sau COOH protejată sau se transformă compusul obținut cu formula generală I într-un derivat al său, acceptabil farmaceutic, dintre N-oxid, N-alchil, o sare, un ester sau amidă sau invers, prin metode în sine cunoscute.
Se dau în continuare exemple de realizare a procedeului conform invenției.
Exemplul 1. 4-[4,5 Dihidro-l-fenil-lHpirazol-3-il] amino-2,6-diinetilfenilacetat
Un amestec format din 0,16 g 4,5-dihidro-l-fenil-lH-pirazol- 3-amină, 0,2 g 4-amino-2,6-dimetilfenilacetat și 0,02 g acid toluen-4-sulfonic se refluxează în toluen sub azot, timp de 8 h. Evaporarea și separarea prin cromatografie (silice, diclormetan/acetat de etil /95:5/) a reziduului conduce la produs pur, în cantitate de 0,15g, solid.
în aceleași condiții arătate mai sus, s-au preparat următorii compuși:
a) 4-[4,5-dihidro-1 -(3-trifluorometilfenil)-lH-pirazol-il] amino 2,6-dimetilfenilacetat, având punctul de topire 190-s-191°C;
b) . 2,6-dimetil-4-[6,7,8,9-tetrahidro-4-o105958 xo-4H-nafto[2,3-b] piran-2-il] aminofenilacetat (din intermediarul sulfoxid), având punct de topire 224 226 °C;
c) 4-(5,6-dietoxi-lH-benzimidazol-2-il) amino-2,6-dimetilfenilacetat (din intermediarul de la exemplul 1), având punct de topire 91+94°C;
d) 2,6-dimetil-4-(chinolin-2-il) aminofenilacetat (din 2-cloro-chinolină), având punct de topire 154+155°C·,
e) 4-(3-aminocarbonilpiridin-2-il)amino-2,6-dimetilfenilacetat (din 2-cloronicotinamidâ), având punct de topire 209+ +211°C;
f) 2,6-dimetil-4-(2-pirimidinil) aminofenilacetat (din 2-cloropirimidină).
Exemplul 2. 4-(I-Feiiil-lH-pirazol-3-il) amino -2,6-di(prop-2-eml) fenilacetat
a) 4-( l-Fenil-lH-pirazol-3-il)ainitio-2(prop-2-enil) fenol
S-au adăugat 19g 4-(l-fenil-lH-pirazol-3-ilaminofenol la 4,0 g suspesie 50% hidrură de sodiu, liberă de ulei, în 150 ml dimetil-formamidă uscată. După 0,5 h s-a adăugat 1,2 ml bromură de alil și amestecul s-a agitat timp de 16 h, s-a turnat în apă și s-a extras cu acetat de etil. Evaporarea solventului și separarea prin cromatografie (silîce/diclormetan) a condus la l-fenil-N-|4-[(prop-2-enil) oxifenil]|-lH-pirazol-3-amină, în cantitate de 121,9g, cu un punct de topire 80+8 Γ C. Solidul (2,9g) a fost.încălzit la 200°C sub βζοζ timp de 5 h. Prin cromatografie (silice/diclormetan) s-au obținut l,4g produs impur, sub forma unui ulei vâscos. ’HNMR tipic (DMSO: 8,7 (1H, -CH=) ox x 5,1 (2H, dd, = CHj) o 3,25 (2H, d, OCHJ
b) 4-l-Fenil-IH-pirazol-34l)amino-2,6-di(prop-2-enil)fenol
10,5g din produsul obținut mai sus a fost convertit printr-un procedeu analog la 7,6g l-fenil-N-(3-[(prop-2-enil) oxifenil])-lH-pirazol-3-amină, sub formă de ulei, și apoi la 5,5g fenolul arătat în titlu, cu punct de topire 87+88°C.
c) 4-(l-Fenil-lH-pirazol-3-il)amino-2,6-di(prop-2-enil) fenil-acetat
La produsul obținut în etapa b), în cantitate de 5,0g în 100 ml diclormetan, care conține 100 mg 4-dimetilaminopiridină și
2,1 ml trietilamină, se adaugă încet, sub agitare, 1,1 ml clorură de acetil. După 6 h se adaugă apă, iar reziduul, după evaporarea fazei organice, se cromatografiază (silice, diclormetan) și apoi se cristalizează din ciclohexan pentru a se obține 4,5g compusul din titlu, cu punct de topire 110+llloC.
în condițiile arătate mai sus, s-au preparat din fenolul corespunzător și clorură de carbonil adecvată, următorii compuși:
a) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)-aminofenilbutanoat, cu punct de topire 138+140’C.
b) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3 -il)-aminofenil-2,2-dimetilpropanQpt, cu punct de topire 139+140°C;
c) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3-il) aminofenil-fenilcarbonat, cu punct de topire 138+139°C;
d) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)-aminofenil-metil-carbont, cu punct de topire 110+112°C;
e) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)aminofenilbenzoat, cu punct de topire 117+118°C;
. f) 2,6-dimetil-4-(l-fenil-lH-pizarol-3-il)-aminofenil-2-metil-propanoat, cu punct de topire 127+128°C;
g) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)aminofcnil-fenilmetilcarbonat, cu punct de topire 105+106°C;
h) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il) aminofenil-4-metoxibenzoat, cut punct de topire 185+187°C;
i) 2,6-dimetil-4-(l -fenil- lH-pirazol-3-il)aminofenil-metoxiacetat, cu punct de topire 149+150°C;
j) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)aminofenil-cloracetat, cu punct de topire
141+142°C;
k) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3il)-aminofenil(l,l-dimetilctil)-carbonat, cu punct dc topire 122+123°C;
l) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3-il)- aminofenil-4-nitrobenzoat, cu punct de topire 210+211°C;
m) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-
3-il)- aminofenil-butil-carbonat, cu punct de topire 72+73°C;
n) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-i1)- aminofenil-3-piridin carboxilat, cu punct de topire 158+16O°C;
o) 2,6-dimetil-4-( 1 -fenil- lH-pirazol-3il)- aminofenil-4-clor-benzoat, cu punct de topire 166+167°C;
p) 2,6-dimetil-4-(l-fenil- lH-pirazol-3-il)- aminofenil-3-metoxi-propanoat, cu punct de topire 125+126°C;
q) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3-il)-«aminofenil-dimetil-carbamat, cu punct de topire 171+173°C;
r) 2,6-dimeti]-4-(l-fenil-]H-pirazol-
3-il)- aminofenil-4-dimetil-amino-4-oxobutanoat, cu punct de topire 210+211°C;
s) 2,6-dimetil-4-(l -fenil-lH-pirazol-3-il)- aminofenil-acetoxietanoat, cu punct de topire 127+128°C.
t) 2,6-dimetil-4-(l-fenil-lH-pirazol-
3-il)- aminofenil-propandioat de metil, cu punct de topire 112+113°C;
u) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3il)- aminofenil-l,5-pentandioat de metil, cu punct de topire 108+109°C;
v) 2,6-dimetil-4-( 1 -fenil- lH-pirazol-3-il)- aminofenil-l,4-butandioat de metil, cu punct de topire 90+91°C;
w) 3,6-dimetoxi-2-metil-4-(l-fenil-lHpirazol-3-il)-aminofenil-acetat, cu punct de topire 132+134°C;
x) 2,6-dimetil-4-[N-metil-N-(l-fenil-lH-pirazol-3-il)]-aminofenil-etanoat, cu punct de topire 111+112°C;
y) 2, 3, 5, 6-tetrametil-4-(l-fenil-lH-piîâzbl-3-il)-aminofenil-acetat, cu punct de topire 179 180 °C;
z) 2,6-diclor-4-(l-fenil-lH-pirazol-3-il)aminofenil-acetat, cu punct de topire 169+ + 170°C;
aa) 2,6-dimetil-4-(l -fenil- lH-pirazol-3-il)- aminofenil-fenilmetoxi-acetat, cu punct de topire 101 + 101,5°C;
ab) 2,5-dimetoxi -4-( 1 -fenil-1 H-pirazol-
3-il)- aminofenil-acetat, cu punct de topire 149+150°C;
ac) benzen-l,4-/nono-[2,6-dimetil-4-( 1fenil-lH-pirazol-3-il)]-aminofenil-dicarboxilat de monofenilmetil.
Exemplul 3. 2,6-bis(l,l-dimetiletil)-4(N-metil-N-/l-fenil-lH-pirazol-3-il/aminofenilacetat
La 0,6g 2,6-bis(l,l-dimetiletil)-4-[Nmetil- N-( 1 -fenil-1 H-pirazol-3-il)amino] fenol în 15 ml tetrahidrofuran uscat, la 78°C, sub azot, se adaugă 1,29 ml soluție
1,4 M butil-litiu în hexan. După 10 min se adaugă 0,2 ml clorură de acetil. Reacția a fost lăsată timp de 16 h, masa de reacție a fost turnată in apă și extrasă cu acetat de etil. Evaporarea și separarea cromatografică (silice, diclormetan/hexan/1:1/) a reziduului, urmată de recristalizare din hexan la -20°C, a condus la 0,35g produs pur, având punctul de topire 102+103°C.
în condițiile de mai sus, utilizând acil cloruri și fenoli corespunzători, s-au preparat următorii compuși:
a) 2,6-bis(l, 1 -dimetiletil)-4-[N-metil-N(1-fenil- lH-pirazol-3-il)amino] fenilmetoxi-acetat, cu punct de topire 102+103°C.
b) 2,6-bis( 1,1 -dimetileti 1)-4-(1 -fenil-1Hpirazol- 3-il)aminofenil-acetat, cu punct de topire 186+187°C.
c) 2,6-bzs(l,l-dimetiletil)-4-[(l,3-difcnil-lH-pirazol-5-il)amino] fenilacetat.
Exemplul 4. 1,4-Butandioic acid, m ono[2,6-dimetil-4- (1 -fenil-1 H-pirazol-3-il) aminofenil] ester
La l,8g 4-(l-fenil-lH-pirazol-3-il) amino-2,6-dimetil fenol în 30 ml diclormetan uscat și 2,25 ml trietilaminâ, la 0°C, sub azot, se adaugă 0,84g anhidridă, succinicâ.
8
Amestecul se agită la temperatura camerei timp de 16 h, apoi se toarnă in apă. Faza organică se usucă și se evaporă. Uleiul rezultat se separă cromatografic (silice, metanol 2% diclormetan) pentru a se obține l,5g produs pur, având punctul de topire 160*161°C, după cristalizare din hexan/acetat de etil.
în aceleași condiții s-a preparat 1,5pentandioic acid, mo?io-[2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)] aminofenil ester, având punctul de topire 138*140°C.
Exemplul 5. 2,6-dimetil-4-(l-fenil-lHpirazol-3-il) aminofenil-2-oxopropanoat.
Se adaugă 4,9g l,l'-carbonildiimidazol, în porțiuni, la 2,6g acid pimvic în 100 ml diclormetan și după 0,5 h se adaugă 2,8g
2,6-dimetil-4-(l-fenil-lH-pirazol-3-il) aminofenol. Amestecul este lăsat timp de 16 h, apoi se evaporat, iar reziduul separat cromatografic (silice/diclormetan), pentru a se obține, după cristalizare din hexan/acetat de etil, l,0g produs pur, având punctul de topire 123*125°C.
în aceleași condiții ca mai sus au fost preparați următorii compuși:
a) 2,6-dimetil-4-( 1 -fenil- lH-pirazol-3-il)- aminofenil N-[(fenilmetoxi) carbonil] glucinat, cu punct de topire 142* 143°C.
b) 2,6-dimetil -4-( 1 -fenil-1 H-pirazol-3-il)- aminofenil-4-dimetil-aminobutanoat, cu punct de topire 83*85°C.
Exemplul 6. 2,6-dimetil-4-(l-fenil- 1Hpirazol-3-il)-aminofenilacetat
Produsul obținut în exemplul 1 a fost refluxat în toluen, în cantitate de 0,15g, cu 5% paladiu pe cărbune, timp de 4 h.
Filtrarea, evaporarea și separarea cromatografîcă (silice, diclormetan/acetat de etil/95:5/ a reziduului a condus la 0,07g produs pur, cu punct de topire 114*116°C (din ciclohexan); mai mult polimorf, punct de topire 134°C.
în aceleași condiții, s-a preparat și 2,6dimetil-4-[l-(3-trifluorometilfenil)-lH-pirazol-3-il] aminofenil-acetat, cu punct de topire 142*143°C.
Exemplul 7. S-au hidrogenat 3,5g.4-(11 fenil-lH-pirazol-3-il) amino-2,6-(prop-2enil) fenilacetat în 150 ml etariol, la presi5 une atmosferică, pe 10% paladiu pe cărbune, pentru a se obține, după cristalizare din ciclohexan, l,8g produs, cu punct de topire 71*74°C, cu denumirea 4-(l-fenillH-pirazol-3-il) amino- 2,6-dipropilfenil10 acetat.
în aceleași condiții, următorii compuși au fost obținuți din precursorii indicați:
a) 2,6-dimetil-4-( 1 -fenil-1 H-pirazol-3-il)aminofenil-hidroxi-acetat, având punctul de topire 155+157°C.
b) 4-(ciclohexil-lH-pirazol-3-il) amino-2,6- dimetilfenil-hidroxi-acetat, având punctul de topire 160*164°C;
a) și b) au fost preparați din 2,6-dimetil20 4-(l-fenil-lH-pirazol-3-il) aminofenil-fe- nilmetoxi-acetat, prin hidrogenare la 5 at, timp de 6 zile, și separarea amestecului de compuși rezultați, prin cromatografie (silice, diclormetan/acetat de etil 9:1;
c) 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il)aminofenil-glucinat-clorhidrat, preparat ca mai sus și urmat de o tratare cu acid clorhidric în eter. Produsul are punctul de topire 230*231°C;
d) acid benzen-1,4-dicarboxilic, mono[2,6- dimetil-4-( 1 -fenil-1 H-pfrazol-3-il) aminofenil] ester, preparat din esterul monobenzil, având, punctul de topire 221* *222°C.
Exemplul 8. 2,6-dimetil-4-(l-fenil-] H-pirazol- 3-il) aminofenil cianoacetat
Un amestec de 2,6-dimetil-4-(l-fenil-lH-pirazol- 3-il)-aminofenil-cloroacetat, lg, și 0,5g cianură de sodiu s-a agitat în dimetil4θ sulfoxid, timp de 16 h, obținându-se, după diluare cu solă, extracție cu acetat de etil și evaporare ulterioară 0,-3g produs, având punctul de topire 116*117°C (din acetat de etil/hexan).
4 5 Exemplul 9. 3-[2,6-dimetil-4-( 1 -fenil-1H-pirazol- 3-il)-aminofenoxicarbonilj-l-metil pirimidin iodură
0,5g 2,6-dimetil -4-( 1 -fenil-1 H-pirazol-
3-il) aminofenil-3-piridincarboxilșt a fost refluxat în 100 ml iodură de metil, timp de 4 zile, iodură de metil nereacționată a fost îndepărtată prin evaporare și s-au obținut 1,15g produs pur, prin trituarea uleiului rezultat cu eter, având punctul de topire 150°C (cu descompunere).
în continuare se dau exemple pentru prepararea intermediarilor.
Exemplul A. 4-Amino-2,6-dimetilfenilacetat
La un amestec, format din lOg 2,6-dimetilnitrofenol și 21 ml trietilamină, în 100 ml diclormetan uscat, la 0°C, s-au adăugat 5,6 ml clorură de acetil, treptat. După 16 h, amestecul a fost spălat cu apă, uscat și evaporat, pentru a se obține 9,4g acetat, cu punct de topire 109-5-H10°C. Acetatul, în cantitate de 9,4g, a fost hidrogenat în etanol la presiune atmosferică pe oxid de platină timp de 4 h. Filtrareaa, evaporarea și cristalizarea (acetat de etil/hexan) reziduului au condus la obținerea de 5,6g produs pur, cu punct de topire 82+83°C.
Exemplul B. 4-amino-3,6-dimetoxi-2metilfenol
Acidul sulfanilic, în cantitate de 10,8g, a fost diazotat pe o cale cunoscută (Organic Syntheses Coli. voi. 2, p. 35). După 20 de minute, suspensia rezultată a fost adăugată la o soluție răcită cu gheață, din 8,lg 3,6-dimetoxi-2-metilfenol și 10,8g hidroxid de sodiu în 100 ml apă. După o oră amestecul a fost încălzit la 45+50°C și s-au adăugat, în porțiuni, 22,2g hidrosulfit de sodiu. Când culoarea roșie a apărut, amestecul a fost răcit, pentru a se obține lOg precipitat galben de sare bisulfiticâ a fenolului pur.
Prin aceeași metodă s-au preparat următorii fenoli, prin intermediul sărurilor lor bisulfitice:
a) 4-âmino-2,6-dimetilfenol;
io
b) 4-amino-2, 3, 4, 5-tetrametilfenol;
c) 4-amino-2,6-6/s(l,l-dimetiletil) fenol Exemplul C. 2,6-dimetil-4-(l-fenil-lH- pirazol-3-il)-aiiiitiofenol
Un amestec format din 15g 2,6-dimetil-4-aminofenol și 17,6g 4,5-dihidro-l-fenil-lH-pirazol-3-amină s-a încălzit cu 0,2g acid p-toluen sulfonic, la 160°C, timp de o oră, sub atmosferă de azot. Amestecul a fost răcit, absorbit în diclormetan și spălat cu acid clorhidric diluat și apă. Evaporarea și separarea prin cromatografie a reziduului (silice, diclormetan/acetat de etil /9:1/) a condus la 14,2g 4-(4,5-dihidro-l-fenil-lH-pirazol-3-il) amino-2,6-dimetil-fenol, cu punct de topire 154^158°C. Acesta a fost refluxat în 40 ml toluen cu lOg paladiu 10% pe cărbune, timp de 3 h. Amestecul a fost filtrat și evaporat pentru a se obține, după cristalizare din ciclohexan/acetat de etil, 8g produs pur, având punctul de topire 154-5-155°C.
Următorii intermediari au fost obținuți prin metoda de mai sus:
a) 2, 3,5, 6-tetrametil-4-(l-fenil-lH-pirazol- 3-il) aminofenol, cu punct de topire 160+162°C;
b) 3,6-dimetoxi-2-metil-4-(l-fenil-lH-pirazol-3-il) aminofenol, cu punct de topire 107-108°C;
c) 2,6-bis( 1,r-dimetiletil)-3-(l-fenil-1Hpirazol- 3-il) aminofenol, cu punct de topire 114+115°C;
d) 2,6-diclor-4-( 1 -fenil-1 H-pirazol-3-il) aminofenol, cu punct de topire 144-5- 146°C.
Exemplul D. 2,6-dimetil-4-[N-metil-N-(l-fenil- lH-pirazol-3-il)-amino] fenol
La 8g 2,6-dimetil-4-(l-fenil-lH-pirazol-3-il) aminofenol, 2,8 ml acid acetic și 3,1 ml fomaldehidâ soluție apoasă 40%, în 40 ml acetonitril, se adaugă 5,4g cianborohidrură de sodiu. După 2 h, amestecul se răcește brusc cu apă și se extrage cu diclormetan. Faza organică se spală cu soluție apoasă de bicarbonat de sodiu, apoi cu apă, se usucă, se evaporă și se separă prin croma tografie (silice, diclormetan), obținându-se 3g compus din titlu, cu punct de topire 139+140°C (din etanol).
Prin aceeași metodă s-a preparat 2,6bis( 1,1- dimetiletil)-4-[N-metil-N-( 1 -fenil-lH-pirazol-3-il)- amino]-fenol, cu punct de topire 117+118°C.
Anumiți - compuși cu formula generală II sunt cunoscuți (EP-A-254.259 sau EP-A-178.035. Unii intermediari cu formula generală Π sunt compuși noi. Astfel, sunt compușii cu formula generală Ila:
în care X, reprezintă lH-pirazol-3-il substituit cu 1-fenil sau 1-trifluormetilfenil, R21 și R*,, care pot fi identici sau diferiți, sunt aleși dintre alchil inferior, halogen și alcoxi inferior, iar RJa Și Rs. reprezintă amândoi hidrogen.
Următorii compuși au fost preparați din aminoheterociclul adecvat, prin metodele descrise în EP-A-254 259:
a) 2,6-dimetil-4-(pirazin-2-il) aminofenol, cu punct de topire 188+190°C.
b) 4-(4-cloro-6-metilpirimidin-2-il) amino-2,6-dimetilfenol, cu punct de- topire 16O+163°C.
Conform invenției, se prevede un procedeu pentru prepararea compușilor cu formula generală I, care consta în reacționarea unui compus cu formula generală Π:
în care X, R2, R3, R4, R5 și R$ au semnificațiile arătate mai sus, cu un compus cu formula generală III:
R,L2 ’ (III) în care R2 este o grupă scindabilă și R, are semnificațiile de mai sus, iar dacă se dorește sau este necesar, se îndepărtează grupa protectoare dintr-un compus corespunzător cu formula generală I, care are o grupă OH, NHR14 sau COOH protejată.
Grupele scindabile pe care le poate reprezenta Lj sunt O-acil, adică compusul III este o anhidridă acidă, imidazolidă sau clorură. Reacția se poate efectua prin amestecarea reactivilor în condiții anhidre, în prezența unui solvent inert, cum ar fi, diclormetanul sau tetrahidrofuranul. Când reactivul cu formula generală III este o halogenură acidă, reacția se efectuează, de preferință, în prezența unei baze, cum este trietilamina și/sau dimetilaminopiridina.
în anumite cazuri, de exemplu, când atât R2, cât și reprezintă grupe voluminoase, cum este grupa fer/-butil, condițiile Schotten-Baumann, în care reacția se efectuează folosind o bază destul de puternică, pentru a scoate un proton din fenolul cu formula generală II, dau rezultate deosebit de bune.
Derivații acceptați farmaceutic ai compușilor cu formula I includ săruri acide de adiție acceptate farmaceutic. Săruri adecvate includ săruri ale acizilor minerali, de exemplu, acizii halogenhidrici, cum ar fi, acidul clorhidric sau acidul bromhidric sau acizi organici, cum sunt acidul formic, acetic sau lactic.
Când compusul cu formula I conține o grupă de acid carboxilic, el poate forma o sare acceptată farmaceutic, ester sau derivat amidic. Sărurile corespunzătoare includ sărurile de amoniu, de metal alcalin (de exemplu, sodiu, potasiu și litiu) și de metal alcalino-pământos (de exemplu, calciu sau magneziu). Esterii corespunzători includ simplii esteri de alchil inferior, ca, esterul etilic. Amidele pot fi, de exemplu, amide
nesubstituite sau mono - sau dialchil-amidc cu 1...6 atonii de carbon la alchil sau fenilamide, putând fi obținute prin procedee cunoscute, de exemplu, prin reacția unui ester de acid corespunzător cu amoniac sau cu o amină adecvată.
Se preferă compușii în care Y este o legătură simplă. Când Y este o legătură simplă, se preferă ca Z să nu fie hidrogen. Când Z reprezintă alchil, se preferă ca acesta să fie alchil inferior, în special alchil cu 1...4 atomi de carbon. Grupa alchil poate fi saturată sau nesaturată și liniară sau ramificată. Grupele speciale alchil, care se pot menționa, sunt metil, etil, n-propil, izopropil, n-butil și terț-butil. Când grupa alchil este substituită, se preferă să fie tri-, di- și mai ales monosubstituită. Substituentul(ții) poate (pot) fi așezat(ți) în orice parte a grupei alchil. însă se preferă acei compuși care conțin un singur substituent plasat la capătul grupei alchil, substituenții specifici care pot fi menționați fiind hidroxi, alcoxi, inferior, de exemplu, metoxi sau etoxi, aciloxi inferior, în special aciloxi cu 1...4 atomi de carbon, de exemplu, acetoxi, propanoiloxi, CONH2, fenilalcoxi, mai ales fenilmetoxi, halogen, mai ales brom și, în special, clor; cian sau amine.
Se preferă compușii cu formula generală I, în care cel puțin unul dintre R2, R3, Rs și R6 este diferit de hidrogen. Se preferă, în mod special, acei compuși în care cel puțin doi dintre R2, R3, Rs și sunt diferiți de hidrogen. Deosebit de preferați sunt acei compuși în care R? și sunt diferiți de hidrogen.
Ca grupă pirazolil specială pe care o poate reprezenta X este grupa ΙΗ-3-pirazolil.
Ca grupe arii speciale pe care le poate reprezenta Ar2 sunt naftalenil și, mai ales, fenil, eventual substituite cu trei, doi sau mai ales cu un singur substituent, ales dintre halogen, de exemplu, clor, fluor sau brom; carboxil; alchil, de preferință alchil inferior, de exemplu, metil, etil, propil sau trihaloalchil, în specia] trihaloalchil inferior, mai ales CF3 sau CH2CF3.
Compușii cu formula generală I și derivații lor acceptabili farmaceutic sunt utili pentru că posedă activitate farmacologică la animale. în special, compușii sunt utili ca agenți antiinflamatori cu spectru larg, mai ales ei fiind inhibitori ai lipoxigenazelor, de exemplu, a lipoxigenazei 5, 12 și 15.
Compușii sunt indicați pentru utilizare în tratamentul sau profilaxia condițiilor inflamatoare la animale, inclusiv la om, mai ales la reumatism, psoriazis, cazuri inflamatoare gastro-intestinale și alte cazuri asociate cu inflamația, în special acelea în care produsele lipoxigenazei și ciclooxigenazei sunt un factor.
Pentru utilizările menționate mai sus, doza administrată va varia, desigur, în funcție de compusul întrebuințat, modul de administrare și tratamentul dorit. Totuși, în general, rezultate satisfăcătoare s-au obținut când compusul a fost administrat într-un dozaj zilnic de aproximativ 0,1 mg până la aproximativ 60 mg per kg greutate corp de animal, preferabil dat în doze de 1 până la 4 ori pe zi sau într-o formă suportabilă. La om, doza zilnică totală este în domeniul de la 0,7 mg până la 4,2 g, iar doza unitară suportabilă pentru administrare orală cuprinde de la 2,0 mg până la
4,2 g de compus, amestecat cu un purtător sau diluent farmaceutic, solid sau lichid.
Compușii cu formula generală I și derivații acestora acceptabili farmaceutic pot fi utilizați ca atare sau sub forma unor preparate medicinale adecvate pentru administrare enterală, parentală sau topicală. Astfel, noii compuși pot fi amestecați cu adjuvanți, diluenți sau purtători acceptați farmaceutic. Se preferă ca compozițiile să conțină până la 50% și mai preferabil până la 25% în greutate compusul cu formula I sau derivații acestuia acceptați farmaceutic.
Compușii cu formula generală I și derivații acestora acceptați farmaceutic au avantajul că sunt mai puțin toxici, mai eficienți, au activitate mai lungă, au un domeniu mai larg de activitate, mai eficace, produc puține efecte secundare, sunt mai selectivi, sunt mai ușor absorbabili, sunt mai stabili sau au alte proprietăți farmaceutic folositoare, în comparație cu compușii cu structură similară.
Claims (1)
- RevendicareProcedeu pentru prepararea unor derivați de aihinofenol cu formula generală I:în care R, repezintă C(O)YZ, Y reprezintă o legătură simplă, O, NR,, sau CO, Z reprezintă hidrogen, alchil sau alchil substituit cu unul sau mai mulți substituenți, aleși dintre hidroxi, alcoxi, aciloxi, carboxi, alcoxicarbonil, CONR12RI3, arilalcoxi, Ar„ heterociclu, halogen, cian, sau NR14R13; R2, Rj, Rs și Rg, care pot fi identici sau diferiți, reprezintă un atom de hidrogen, radicali alchil, alcoxi sau halogen, cu condiția ca cel puțin unul dintre R2 și R^ să fie diferit de hidrogen sau R2 și R^ reprezintă ambii radicali alchil sau Rj și Rj reprezintă amândoi atomi de hidrogen; R4 și R,„ care pot fi identici sau diferiți, reprezintă atomi de . 40 hidrogen sau radicali alchil, X reprezintă pirazolil substituit cu Ar2; Ar, și Ar2, care pot fi identici sau diferiți, reprezintă arii satj arii substituit cu unul sau mai mulți substituenți, aleși dintre halogen, nitro, 5 alcoxi, carboxi, alchil sau trihaloalchil,R12,R|J» R|4> R|S» R|6» ^17» Rll Ș* R|9» Cafe P°t fi identici sau diferiți, reprezintă atomi de hidrogen, radicali alchil sau benziloxicarbonil sau derivați acceptabili farmaceutic ai 10 acestora, și anume, N-oxid, N-alchil, o sare, un ester sau o amidă, caracterizat prin aceea că, în scopul lărgirii gamei compușilor cu proprietăți antiinflamatoare, se esterifică un compus cu formula generală 15 II:în care, X, R2, R3, R4, Rs și R6 au semnificațiile de mai sus, cu un compus cu for2^ mula generală III:R,L2 (III) în care R, are semnificația de mai sus și Lj este o grupă scindabijă, cum este o clorură sau O-acil, în prezența unei baze, cum este trietilamina sau dimetilaminopiridina, într-un solvent inert, cum este diclormetanul sau tetrahidrofiiranul, iar dacă se dorește sau este necesar, se îndepărtează grupa protectoare dintr-un compus cu formula generală I, care are o grupă OH, NHR14 sau COOH protejată sau se transformă compusul obținut cu formula generală I într-un derivat al său, acceptabil farmaceutic, dintre N-oxid, N-alchil, o sare, un ester sau o amidă sau invers, prin metode în sine cunoscute.
Priority Applications (32)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898911655A GB8911655D0 (en) | 1989-05-20 | 1989-05-20 | Compound |
GB898911654A GB8911654D0 (en) | 1989-05-20 | 1989-05-20 | Compound |
GB909003044A GB9003044D0 (en) | 1990-02-10 | 1990-02-10 | Compounds |
MX2069690A MX20696A (es) | 1989-05-20 | 1990-05-14 | Derivados de aminofenol antiinflamatorios y procedimiento para su obtencion |
GR900100380A GR900100380A (el) | 1989-05-20 | 1990-05-16 | Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης. |
ZA903802A ZA903802B (en) | 1989-05-20 | 1990-05-17 | Anti inflammatory aminophenol derivatives |
AT90908298T ATE126215T1 (de) | 1989-05-20 | 1990-05-17 | Anti-entzündende 4-aminophenol-derivate. |
AU56682/90A AU630196B2 (en) | 1989-05-20 | 1990-05-17 | Heterocyclic substituted 4-amino phenol derivatives |
EP90908298A EP0425650B1 (en) | 1989-05-20 | 1990-05-17 | Anti-inflammatory 4-aminophenol derivatives |
PCT/GB1990/000762 WO1990014338A1 (en) | 1989-05-20 | 1990-05-17 | Anti-inflammatory 4-aminophenol derivatives |
DE69021501T DE69021501T2 (de) | 1989-05-20 | 1990-05-17 | Anti-entzündende 4-aminophenol-derivate. |
ES90908298T ES2077066T3 (es) | 1989-05-20 | 1990-05-17 | Derivados de 4-aminofenol anti-inflamatorio. |
DK90908298.4T DK0425650T3 (da) | 1989-05-20 | 1990-05-17 | Antiinflammatoriske 4-aminophenolderivater |
SU904894663A RU2049779C1 (ru) | 1989-05-20 | 1990-05-17 | Производные 4-аминофенола или их n-алкильные или солевые производные, проявляющие противовоспалительную активность |
JP2507734A JPH07116155B2 (ja) | 1989-05-20 | 1990-05-17 | 抗炎症性4―アミノフェノール誘導体 |
PL90285248A PL164432B1 (pl) | 1989-05-20 | 1990-05-18 | Sposób wytwarzania nowych pochodnych aminofenolu PL |
CS902444A CZ280637B6 (cs) | 1989-05-20 | 1990-05-18 | Deriváty aminofenolu a způsob jejich výroby |
PL90289487A PL164480B1 (pl) | 1989-05-20 | 1990-05-18 | Sposób wytwarzania nowych pochodnych aminofenolu PL |
IE179990A IE68410B1 (en) | 1989-05-20 | 1990-05-18 | Anti-inflammatory 4-aminophenol derivatives |
NZ233735A NZ233735A (en) | 1989-05-20 | 1990-05-18 | Heterocyclic substituted aminophenol derivatives |
IL9443390A IL94433A (en) | 1989-05-20 | 1990-05-18 | Pharmaceutical preparations containing a history of aminophenol, such new compounds and their preparation |
DD340830A DD300544A5 (de) | 1989-05-20 | 1990-05-18 | Entzündungshemmende Aminophenolderivate |
PH40534A PH27048A (en) | 1989-05-20 | 1990-05-18 | Anti-inflammatory aminophenol derivatives |
HU903094A HU206323B (en) | 1989-05-20 | 1990-05-18 | Process for producing antiphlogistic pyrazolyl-amino-phenol-derivatives and pharmaceutical compositions containing them as active components |
CA002017169A CA2017169A1 (en) | 1989-05-20 | 1990-05-18 | Anti-inflammatory aminophenol derivatives |
PT94085A PT94085B (pt) | 1989-05-20 | 1990-05-18 | Processo para a preparacao de derivados de amino-fenol anti-inflamatorios |
CN90103739A CN1047497A (zh) | 1989-05-20 | 1990-05-19 | 抗炎药氨基苯酚衍生物 |
RO145922A RO105958B1 (ro) | 1989-05-20 | 1990-09-12 | Procedeu pentru prepararea unor derivati de aminofenol |
FI910222A FI910222A0 (fi) | 1989-05-20 | 1991-01-16 | Anti-inflammatoriska 4-aminofenolderivat. |
NO91910198A NO910198L (no) | 1989-05-20 | 1991-01-17 | Anti-inflammatoriske 4-aminofenolderivater. |
HR930239A HRP930239A2 (en) | 1989-05-20 | 1993-02-26 | Anti-inflamatory 4-aminophenol derivatives |
US08/138,375 US5428044A (en) | 1989-05-20 | 1993-10-15 | Anti-inflammatory 4-aminophenyl derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898911654A GB8911654D0 (en) | 1989-05-20 | 1989-05-20 | Compound |
GB898911655A GB8911655D0 (en) | 1989-05-20 | 1989-05-20 | Compound |
GB909003044A GB9003044D0 (en) | 1990-02-10 | 1990-02-10 | Compounds |
RO145922A RO105958B1 (ro) | 1989-05-20 | 1990-09-12 | Procedeu pentru prepararea unor derivati de aminofenol |
Publications (1)
Publication Number | Publication Date |
---|---|
RO105958B1 true RO105958B1 (ro) | 1993-01-30 |
Family
ID=27450337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RO145922A RO105958B1 (ro) | 1989-05-20 | 1990-09-12 | Procedeu pentru prepararea unor derivati de aminofenol |
Country Status (25)
Country | Link |
---|---|
US (1) | US5428044A (ro) |
EP (1) | EP0425650B1 (ro) |
JP (1) | JPH07116155B2 (ro) |
CN (1) | CN1047497A (ro) |
AT (1) | ATE126215T1 (ro) |
AU (1) | AU630196B2 (ro) |
CA (1) | CA2017169A1 (ro) |
CZ (1) | CZ280637B6 (ro) |
DD (1) | DD300544A5 (ro) |
DE (1) | DE69021501T2 (ro) |
DK (1) | DK0425650T3 (ro) |
ES (1) | ES2077066T3 (ro) |
FI (1) | FI910222A0 (ro) |
GR (1) | GR900100380A (ro) |
HR (1) | HRP930239A2 (ro) |
HU (1) | HU206323B (ro) |
IE (1) | IE68410B1 (ro) |
IL (1) | IL94433A (ro) |
NZ (1) | NZ233735A (ro) |
PH (1) | PH27048A (ro) |
PL (2) | PL164432B1 (ro) |
PT (1) | PT94085B (ro) |
RO (1) | RO105958B1 (ro) |
RU (1) | RU2049779C1 (ro) |
WO (1) | WO1990014338A1 (ro) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
EP0641785B1 (en) * | 1991-09-02 | 1999-10-27 | Yamanouchi Pharmaceutical Co. Ltd. | Triazolylated tertiary amine compound or salt thereof |
GB9127252D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
WO1993015060A1 (en) * | 1992-01-22 | 1993-08-05 | Nissan Chemical Industries, Ltd. | Substituted pyrazole derivative and agrohorticultural bactericide |
GB9312891D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
US6124289A (en) * | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
FR2781147B1 (fr) | 1998-07-20 | 2000-09-15 | Oreal | Compositions pour la teinture des fibres keratiniques contenant des derives de 3-amino pyrazolines a titre de coupleur, procede de teinture et kit de teinture |
WO2003002544A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
GB0127923D0 (en) | 2001-11-21 | 2002-01-16 | Sterix Ltd | Compound |
AU2002339192A1 (en) * | 2001-11-21 | 2003-06-10 | Sterix Limited | 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors |
GB0215775D0 (en) * | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
DE10304294A1 (de) * | 2003-02-04 | 2004-08-12 | Aventis Pharma Deutschland Gmbh | N-Substituierte(Benzoimidazol-2-yl)-phenyl, Verfahren zu ihrer Herstellung , ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
US20050054705A1 (en) | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
DE10304374A1 (de) * | 2003-02-04 | 2004-08-05 | Aventis Pharma Deutschland Gmbh | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9161894B2 (en) | 2011-03-01 | 2015-10-20 | Npharmakon, Llc | Use of N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine and related compounds |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
JP2016501203A (ja) | 2012-11-20 | 2016-01-18 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インドールアミン2,3−ジオキシゲナーゼの阻害剤として有用な化合物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1810267A (en) * | 1927-12-07 | 1931-06-16 | Winthrop Chem Co Inc | Alkyl-quinolyl-amino-phenyl carboxylic acids |
GB321738A (en) * | 1928-08-21 | 1929-11-21 | Ig Farbenindustrie Ag | Process for the manufacture of phenylcarboxylic acid compounds |
US2748122A (en) * | 1954-05-06 | 1956-05-29 | Searle & Co | 2-anilino-4, 6-dimethylpyrimidines |
US3435041A (en) * | 1966-01-19 | 1969-03-25 | Colgate Palmolive Co | 2-anilinoquinolines |
DE2260827C3 (de) * | 1972-12-13 | 1980-11-13 | Basf Ag, 6700 Ludwigshafen | 2,6-Diaminopyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Kupplungskomponenten für Azofarbstoffe |
US3864359A (en) * | 1972-05-01 | 1975-02-04 | American Cyanamid Co | 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and method of preparation thereof |
DE2747531A1 (de) * | 1977-10-22 | 1979-04-26 | Basf Ag | Substituierte 3-aminopyrazole |
YU118379A (en) * | 1978-05-24 | 1983-02-28 | Byk Gulden Lomberg Chemischefa | Process for preparing phenylaminothiophene acetic acid |
AU5319479A (en) * | 1978-12-22 | 1980-06-26 | Ici Australia Limited | Pyrimidinyl amino phenoxy carboxylate derivatives |
DK270880A (da) * | 1979-07-09 | 1981-01-10 | Gulf Oil Corp | Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler |
DE3172309D1 (en) * | 1980-06-27 | 1985-10-24 | Beiersdorf Ag | Substituted 3,5-diamino-1,2,4-oxadiazoles and 3,5-diamino-1,2,4-thiadiazoles, their preparation and pharmaceutical compositions containing them |
EP0046138B1 (de) * | 1980-08-08 | 1985-12-04 | Ciba-Geigy Ag | Verfahren zur Herstellung von 3-(N-Arylamino)-tetrahydrothiophen-2-on-derivaten |
JPS57203072A (en) * | 1981-06-05 | 1982-12-13 | Sankyo Co Ltd | 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient |
US4383851A (en) * | 1981-08-03 | 1983-05-17 | The Dow Chemical Company | 2-Amino-6-fluoronicotinic acids and derivatives thereof and methods of herbicidal use |
DE3134842A1 (de) * | 1981-09-03 | 1983-03-17 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue anilino-1,2,3-triazol-derivate, diese enthaltende arzneimittel sowie verfahren zu deren herstellung und deren verwendung |
DK130584A (da) * | 1983-04-08 | 1984-10-09 | Ciba Geigy Ag | N-(2-nitrophenyl)-4-amino-pyrimidin-derivater samt deres fremstilling og anvendelse som mikrobicider |
US4824859A (en) * | 1983-05-21 | 1989-04-25 | Fisons Plc. | Pyrazoline compounds compositions and use |
EP0178035B1 (en) * | 1984-05-12 | 1990-01-03 | FISONS plc | Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation |
US4614742A (en) * | 1985-08-29 | 1986-09-30 | S.D.S. Biotech K.K. | Fluorinated isophthalonitrile compound and nonmedical fungicide containing the same |
JPH0629263B2 (ja) * | 1985-10-30 | 1994-04-20 | クミアイ化学工業株式会社 | ピリミジン誘導体および農園芸用殺菌剤 |
DE3773746D1 (en) * | 1986-05-07 | 1991-11-21 | Fisons Plc | Pyrazole. |
DK377487A (da) * | 1986-07-21 | 1988-01-22 | Otsuka Pharma Co Ltd | P-aminophenolderivater |
ATE63907T1 (de) * | 1986-11-04 | 1991-06-15 | Duphar Int Res | Substituierte 2-phenylimino-oxazolidin-derivate mit herbizider wirkung. |
-
1990
- 1990-05-16 GR GR900100380A patent/GR900100380A/el unknown
- 1990-05-17 JP JP2507734A patent/JPH07116155B2/ja not_active Expired - Lifetime
- 1990-05-17 DE DE69021501T patent/DE69021501T2/de not_active Expired - Fee Related
- 1990-05-17 DK DK90908298.4T patent/DK0425650T3/da active
- 1990-05-17 AU AU56682/90A patent/AU630196B2/en not_active Ceased
- 1990-05-17 ES ES90908298T patent/ES2077066T3/es not_active Expired - Lifetime
- 1990-05-17 RU SU904894663A patent/RU2049779C1/ru active
- 1990-05-17 AT AT90908298T patent/ATE126215T1/de not_active IP Right Cessation
- 1990-05-17 WO PCT/GB1990/000762 patent/WO1990014338A1/en active IP Right Grant
- 1990-05-17 EP EP90908298A patent/EP0425650B1/en not_active Expired - Lifetime
- 1990-05-18 PL PL90285248A patent/PL164432B1/pl unknown
- 1990-05-18 PT PT94085A patent/PT94085B/pt not_active IP Right Cessation
- 1990-05-18 CA CA002017169A patent/CA2017169A1/en not_active Abandoned
- 1990-05-18 NZ NZ233735A patent/NZ233735A/xx unknown
- 1990-05-18 IE IE179990A patent/IE68410B1/en not_active IP Right Cessation
- 1990-05-18 IL IL9443390A patent/IL94433A/en not_active IP Right Cessation
- 1990-05-18 CZ CS902444A patent/CZ280637B6/cs unknown
- 1990-05-18 PL PL90289487A patent/PL164480B1/pl unknown
- 1990-05-18 DD DD340830A patent/DD300544A5/de unknown
- 1990-05-18 HU HU903094A patent/HU206323B/hu not_active IP Right Cessation
- 1990-05-18 PH PH40534A patent/PH27048A/en unknown
- 1990-05-19 CN CN90103739A patent/CN1047497A/zh active Pending
- 1990-09-12 RO RO145922A patent/RO105958B1/ro unknown
-
1991
- 1991-01-16 FI FI910222A patent/FI910222A0/fi not_active Application Discontinuation
-
1993
- 1993-02-26 HR HR930239A patent/HRP930239A2/xx not_active Application Discontinuation
- 1993-10-15 US US08/138,375 patent/US5428044A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RO105958B1 (ro) | Procedeu pentru prepararea unor derivati de aminofenol | |
KR930005002B1 (ko) | 피리돈카복실산 유도체의 제조방법 | |
NO165147B (no) | 1h-imidazo(4,5-c)-kinolin-5-oxydforbindelser. | |
ZA200200177B (en) | Indole derivatives and their use for the treatment of osteoporosis amongst other applications. | |
HU206118B (en) | Process for producing beta-lactam derivatives and pharmaceutical compositions comprising same | |
US3705175A (en) | Indazole-3-carboxylic amides | |
JP3119758B2 (ja) | 7−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬 | |
US4563448A (en) | Bactericidal agents | |
SE442865B (sv) | Farmaceutiskt aktiva 2-substituerade-5-hydroxi-1h-imidazol-4-karboxamidderivat | |
US3726880A (en) | Organic amides and methods for their production | |
US5990106A (en) | Bicyclic amino group-substituted pyridonecarboxylic acid derivatives, esters thereof and salts thereof, and bicyclic amines useful as intermediates thereof | |
US5294718A (en) | Piperidino-3,4-dihydrocarbostyril compounds | |
JP4173599B2 (ja) | 6−ヒドロキシ−2−オキソ−1,2,3,4−テトラヒドロキノリンの製造方法 | |
US5179105A (en) | Phenoxyacetic acid compounds, method for production thereof, and pharmaceutical preparations containing same | |
FR2758326A1 (fr) | Derives de pyridone, leur prepaparation et leur utilisation comme intermediaires de synthese | |
JPS6047264B2 (ja) | チアゾリジン誘導体 | |
JPH03169877A (ja) | 1―メトキシピリミジニル―1h―1,2,4―トリアゾール―3―スルホン酸ニトロアニリド、その製造方法、該化合物を含有する除草剤および該除草剤の製造方法 | |
JPH064625B2 (ja) | 置換イソキノリン誘導体および抗潰瘍剤 | |
US4009173A (en) | Butyrophenone derivatives | |
SU1574598A1 (ru) | Способ получени 4-диалкиламино-2-алкил(или фенил)нафто[2,3- @ ]хинолин-7,12-дионов | |
KR100236852B1 (ko) | 플루오로 퀴놀린 유도체 | |
JP3332171B2 (ja) | チエノ〔3,2−b〕ピリジン誘導体の製造方法 | |
KR100485634B1 (ko) | 신규피리돈카르복실산유도체또는그염및그물질을유효성분으로하는항균제 | |
JPH0764854B2 (ja) | 新規な4,7―ジヒドロイソチアゾロ[5,4―bピリジン誘導体及びその製造法 | |
JPS61161263A (ja) | 1,4−ジヒドロピリジンモノエステルモノカルボン酸の製造法 |